Overview
Melrose Industries PLC is a UK-based company specializing in the acquisition and management of underperforming manufacturing companies, which it aims to restructure and sell for a profit. Founded in 2003 and headquartered in London, Melrose operates primarily within the aerospace, automotive, and other industrial sectors. The company is known for its buy, improve, sell strategy; notable transactions include the acquisition and subsequent operational enhancement of GKN, a global engineering business. Melrose focuses on generating shareholder value through significant operational improvements and strategic asset management, positioning itself as a revitalizing force within the complex landscape of global manufacturing industries. Additionally, Melrose is committed to environmental and social governance, actively pursuing sustainability within its operational practices and investments.
Basic Stats
The share price of Melrose Industries PLC as of June 10, 2024 is $8.00 / share. The market cap (or net worth) of Melrose Industries PLC as of September 5, 2025 is $10,232.00 MM.
The Factor Analysis chart (below right) shows a view of Melrose Industries PLC from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 10,232.00 MM |
| EV | |
| Shares Out. | 1,279.00 MM |
| Earnings Date | |
| EPS (TTM) | 0.25 |
| Dividend Yield | |
| Ex-Dividend Date | 2025-08-14 |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | 0.04 |
| ROE | 0.10 |
| ROIC | 0.07 |
| CROIC | -0.01 |
| OCROIC | -0.00 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Melrose Industries PLC is $8.93. The forecasts range from a low of $5.62 to a high of $11.90. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Melrose Industries PLC. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2024-03-08 | Numis | Add | Reiterate | |
| 2023-05-25 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2023-05-24 | Citigroup | Buy | Reiterate | |
| 2023-04-24 | Citigroup | Buy | Reiterate | |
| 2023-02-10 | RBC Capital Markets | Outperform | Reiterate | |
| 2023-01-20 | JP Morgan Cazenove | Not Rated | Reiterate | |
| 2023-01-19 | Numis | Buy | Reiterate | |
| 2023-01-18 | RBC Capital Markets | Outperform | Reiterate | |
| 2022-09-13 | Barclays | Overweight | Reiterate | |
| 2022-09-13 | Deutsche | Buy | Reiterate | |
| 2022-08-08 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2022-05-09 | Barclays | Overweight | Reiterate | |
| 2022-05-04 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2022-04-13 | Citigroup | Buy | Reiterate | |
| 2022-03-15 | Barclays | Overweight | Reiterate | |
| 2022-01-31 | RBC Capital Markets | Reiteration | Reiterate | |
| 2021-10-15 | Barclays | Overweight | Reiterate | |
| 2021-10-07 | Morgan Stanley | Equal-weight | Reiterate | |
| 2021-09-03 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2021-07-29 | Citigroup | Buy | Reiterate | |
| 2021-07-20 | Barclays | Overweight | Reiterate | |
| 2021-06-22 | Peel Hunt LLP | Buy | Reiterate | |
| 2017-03-13 | UBS | Buy | Reiterate | |
| 2017-03-06 | Deutsche Bank | Hold | Reiterate | |
| 2017-03-03 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2017-02-14 | UBS | Buy | Reiterate | |
| 2017-01-11 | Bank of America | Buy | Reiterate | |
| 2016-11-17 | Deutsche Bank | Hold | Reiterate | |
| 2016-11-16 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2016-09-01 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2016-08-09 | Numis | Hold | Reiterate | |
| 2016-07-15 | Numis | Add | Reiterate | |
| 2016-07-13 | Exane BNP Paribas | Neutral | Reiterate | |
| 2016-06-27 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2016-03-24 | UBS | Buy | Reiterate | |
| 2016-03-24 | Credit Suisse | Outperform | Reiterate | |
| 2016-03-08 | Exane BNP Paribas | Neutral | Reiterate | |
| 2016-03-04 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2016-03-03 | Investec | Buy | Reiterate | |
| 2016-02-26 | UBS | Buy | Reiterate | |
| 2016-02-16 | UBS | Buy | Reiterate | |
| 2021-05-21 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2021-05-21 | Barclays | Overweight | Reiterate | |
| 2021-05-07 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2021-05-06 | Numis | Add | Reiterate | |
| 2021-03-11 | Citigroup | Buy | Reiterate | |
| 2021-01-14 | Barclays | Overweight | Reiterate | |
| 2020-07-13 | Morgan Stanley | Equal-weight | Reiterate | |
| 2020-05-14 | Citigroup | Buy | Reiterate | |
| 2019-10-14 | Investec | Buy | Reiterate | |
| 2019-10-10 | Bank of America | Buy | Reiterate | |
| 2019-09-09 | Citigroup | Buy | Reiterate | |
| 2019-09-06 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2019-09-05 | UBS | Buy | Reiterate | |
| 2019-08-30 | RBC Capital Markets | Top Pick | Reiterate | |
| 2019-04-04 | Deutsche Bank | Buy | Reiterate | |
| 2019-04-04 | Peel Hunt LLP | Buy | Reiterate | |
| 2019-03-13 | Goldman Sachs | Buy | Reiterate | |
| 2019-01-08 | Bank of America | Buy | Reiterate | |
| 2018-09-11 | Deutsche Bank | Buy | Reiterate | |
| 2018-09-10 | Barclays | Overweight | Reiterate | |
| 2018-09-06 | Peel Hunt LLP | Buy | Reiterate | |
| 2018-09-04 | UBS | Buy | Reiterate | |
| 2018-08-23 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2018-07-02 | Peel Hunt LLP | Buy | Reiterate | |
| 2018-06-25 | Peel Hunt LLP | Buy | Reiterate | |
| 2018-03-23 | Deutsche Bank | Hold | Reiterate | |
| 2017-12-04 | Numis | Buy | Reiterate | |
| 2017-11-24 | RBC Capital Markets | Outperform | Reiterate | |
| 2017-11-21 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2017-10-13 | Deutsche Bank | Hold | Reiterate | |
| 2017-09-05 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2017-08-02 | Goldman Sachs | Buy | Initiate | |
| 2016-02-11 | Investec | Buy | Reiterate | |
| 2016-02-09 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2016-01-26 | Exane BNP Paribas | Neutral | Reiterate | |
| 2015-12-01 | Citigroup | Neutral | Reiterate | |
| 2015-11-20 | Investec | Add | Reiterate | |
| 2015-11-20 | RBC Capital Markets | Outperform | Reiterate | |
| 2015-11-19 | Goldman Sachs | Buy | Reiterate | |
| 2015-11-13 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2015-10-30 | Credit Suisse | Outperform | Reiterate | |
| 2015-10-20 | Canaccord Genuity | Buy | Reiterate | |
| 2015-10-19 | Goldman Sachs | Buy | Reiterate | |
| 2015-10-08 | Investec | Buy | Reiterate | |
| 2015-10-06 | Credit Suisse | Outperform | Reiterate | |
| 2015-09-21 | Exane BNP Paribas | Neutral | Reiterate | |
| 2015-07-29 | Numis | Add | Reiterate | |
| 2015-07-29 | Goldman Sachs | Buy | Reiterate | |
| 2015-05-19 | Credit Suisse | Outperform | Reiterate | |
| 2015-05-15 | Exane BNP Paribas | Outperform | Reiterate | |
| 2015-05-14 | Investec | Buy | Reiterate | |
| 2015-04-14 | Credit Suisse | Outperform | Reiterate | |
| 2015-03-09 | Charles Stanley | Accumulate | Reiterate | |
| 2015-03-05 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2015-03-05 | Credit Suisse | Outperform | Reiterate | |
| 2015-03-04 | Investec | Buy | Reiterate | |
| 2015-02-03 | Investec | Buy | Reiterate | |
| 2015-01-14 | Beaufort Securities | Buy | Reiterate | |
| 2015-01-12 | Investec | Buy | Reiterate | |
| 2014-12-11 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2014-11-20 | Credit Suisse | Neutral | Reiterate | |
| 2014-11-20 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2014-11-20 | Exane BNP Paribas | Outperform | Reiterate | |
| 2014-11-19 | Charles Stanley | Hold | Reiterate | |
| 2014-11-19 | Liberum Capital | Buy | Reiterate | |
| 2014-11-19 | Investec | Buy | Reiterate | |
| 2014-10-16 | Exane BNP Paribas | Outperform | Reiterate | |
| 2014-10-14 | Canaccord Genuity | Buy | Reiterate | |
| 2014-10-13 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2014-10-13 | Numis Securities | Buy | Reiterate | |
| 2014-10-13 | Investec | Buy | Reiterate | |
| 2014-10-13 | Liberum Capital | Buy | Reiterate | |
| 2014-10-01 | Credit Suisse | Neutral | Reiterate | |
| 2014-10-01 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2014-09-30 | Canaccord Genuity | Buy | Reiterate | |
| 2014-09-30 | Investec | Buy | Reiterate | |
| 2014-09-25 | Exane BNP Paribas | Outperform | Reiterate | |
| 2014-09-05 | Numis Securities | Add | Reiterate | |
| 2014-08-29 | Beaufort Securities | Buy | Reiterate | |
| 2014-08-28 | Liberum Capital | Buy | Reiterate | |
| 2014-08-28 | Canaccord Genuity | Buy | Reiterate | |
| 2014-08-28 | Investec | Buy | Reiterate | |
| 2014-07-22 | Investec | Buy | Reiterate | |
| 2014-07-02 | Credit Suisse | Neutral | Reiterate | |
| 2014-05-13 | Canaccord Genuity | Buy | Reiterate | |
| 2014-05-13 | Charles Stanley | Hold | Reiterate | |
| 2014-05-13 | Numis Securities | Hold | Reiterate | |
| 2014-03-20 | Liberum Capital | Buy | Reiterate | |
| 2014-03-06 | UBS | Neutral | Reiterate | |
| 2014-03-06 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2014-03-05 | Canaccord Genuity | Buy | Reiterate | |
| 2014-01-22 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2014-01-21 | Investec | Buy | Reiterate | |
| 2014-01-13 | Investec | Buy | Reiterate | |
| 2013-12-12 | Credit Suisse | Neutral | Reiterate | |
| 2013-12-10 | Liberum Capital | Buy | Reiterate | |
| 2013-11-26 | Numis Securities | Hold | Initiate | |
| 2013-11-20 | UBS | Neutral | Reiterate | |
| 2013-10-31 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2013-10-16 | Bank of America | Buy | Reiterate | |
| 2013-10-08 | Credit Suisse | Neutral | Reiterate | |
| 2013-09-17 | Bank of America | Buy | Reiterate | |
| 2013-08-30 | RBC Capital Markets | Outperform | Reiterate | |
| 2013-08-29 | Liberum Capital | Buy | Reiterate | |
| 2013-08-29 | Investec | Buy | Reiterate | |
| 2013-08-13 | Bank of America | Buy | Reiterate | |
| 2013-07-01 | Investec | Buy | Reiterate | |
| 2013-06-20 | Investec | Buy | Reiterate | |
| 2013-06-18 | Credit Suisse | Neutral | Reiterate | |
| 2025-01-07 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2024-09-06 | Morgan Stanley | Equal Weight | Initiate | |
| 2024-09-13 | Deutsche | Hold | Reiterate | |
| 2025-01-23 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2025-08-01 | RBC Capital Markets | Outperform | Reiterate | |
| 2025-08-01 | Peel Hunt Limited | Buy | Reiterate | |
| 2024-12-05 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2025-07-02 | JP Morgan Cazenove | Overweight | Reiterate |
